Although similar models have previously been published upon [10,45,46], to our knowledge this is the first report of a model which has been proven to be syngeneically engraftable and is driven by relevant genetic drivers to prostate cancer (Pten and trp53), and mirrors clinical response. This evidence concerns the gene PTEN and Familial prostate cancer.